Soy isoflavones attenuate human monocyte adhesion to endothelial cell-specific CD54 by inhibiting monocyte CD11a.
Soy-based diets have been shown to protect against the development of atherosclerosis; however, the underlying mechanism(s) remain unknown. Interaction between activated monocytes and inflamed endothelial cells is an early event in atherogenesis. Therefore, we examined whether treatment of monocytes with soy phytochemicals could inhibit their adhesion to the endothelial cell-specific protein, CD54, a key factor in monocyte adhesion. Female Sprague-Dawley rats were fed AIN-93G diets containing soy protein isolate or casein. Sera from soy-fed rats inhibited CD54-dependent monocyte adhesion, whereas sera from casein-fed rats did not. To determine whether isoflavones in the sera of soy-fed rats were involved in this inhibition, monocytes were preincubated with soy isoflavones. Isoflavone treatment inhibited monocyte adhesion to CD54 protein, as well as to endothelial cells expressing CD54. Monocyte expression of CD11a, the cognate receptor for CD54, was unaffected by isoflavones. However, binding of the activation epitope-specific antibody mAb24, which binds specifically to the active form of CD11a, was significantly lower in soy isoflavone-treated monocytes than in media-treated cells. These findings suggest that inhibition of CD54-dependent monocyte adhesion by soy isoflavones is mediated in part by affinity regulation of CD11a. Inhibition of monocyte adhesion to endothelial cells by isoflavones resulted in reduced expression of the inflammatory cytokines IL-6 and IL-8. Collectively, these data suggest that the athero-protective effect of soy diets may be mediated by blocking monocyte-endothelial cell interaction.
Nagarajan
Shanmugam
S
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. nagarajanshanmugam@uams.edu
Stewart
Bradford W
BW
Badger
Thomas M
TM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D040881:CD11a Antigen / Q000187:drug effects* / Q000276:immunology; D002364:Caseins / Q000008:administration & dosage; D002448:Cell Adhesion / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D042783:Endothelial Cells / Q000737:chemistry*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D007529:Isoflavones / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000494:pharmacology; D009000:Monocytes / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D030262:Soybean Proteins / Q000008:administration & dosage; D013025:Glycine max / Q000737:chemistry*; D014471:Umbilical Veins / Q000166:cytology
D000911:Antibodies, Monoclonal; D040881:CD11a Antigen; D002364:Caseins; D015850:Interleukin-6; D016209:Interleukin-8; D007529:Isoflavones; D008077:Lipoproteins, LDL; D030262:Soybean Proteins; C099252:oxidized low density lipoprotein; D018799:Intercellular Adhesion Molecule-1